618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

• Syed Kazmi,
• Lijun Sun,
• Angela Alistar,
• Ezra Cohen,
• Timothy Yap,
• Devalingam Mahalingam,
• Justin C Moser,
• Edward Garmey,
• Teresa Mooneyham

Affiliations

Syed Kazmi

5UT Southwestern, Dallas, TX, USA

Lijun Sun

6ImmuneSensor, Dallas, TX, USA

Angela Alistar

2Atlantic Health System, Morristown, NJ, USA

Ezra Cohen

3University of California San Diego, La Jolla, CA, USA

Timothy Yap

7The University of Texas, Houston, TX, USA

Devalingam Mahalingam

8Northwestern University, Chicago, IL, USA

Justin C Moser

1HonorHealth Research Instittue, Scottsdale, AZ, USA

Edward Garmey

4ImmunSensor, Dallas, TX, USA

Teresa Mooneyham

6ImmuneSensor, Dallas, TX, USA